EMA Recommends Granting a Marketing Authorisation for Aumolertinib By Ogkologos - January 8, 2026 444 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with EGFR-mutated NSCLC Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Fruquintinib May 13, 2024 Dr. Alan S. Rabson, Long-Time NCI Deputy Director and Cancer Research... July 5, 2018 PSMA PET-CT Accurately Detects Prostate Cancer Spread, Trial Shows May 11, 2020 ¿Qué son los biosimilares para el tratamiento del cáncer? November 30, 2021 Load more HOT NEWS Marshall University Study Finds That Walnuts Suppress Breast Cancer Growth And... EMA Recommends Extending Indications for Lisocabtagene Maraleucel Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy,... Toddler Hailed A Hero After He Saved His Family From Fire...
